Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 4/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4127705 | 0.91 | FDFT1 (0.38) | FDFT1LPAR1ATRALDH1A1MAPT | |
| SCHEMBL4124464 | 0.86 | LPAR1 (0.43) | FDFT1LPAR1ALDH1A1MAPTKDM4E | |
| SCHEMBL13776019 | 0.85 | LPAR1 (0.45) | FDFT1LPAR1ALDH1A1MAPTKDM4E | |
| SCHEMBL13776116 | 0.83 | LMNA (0.41) | FDFT1ALDH1A1MAPTKDM4ENPC1 | |
| SCHEMBL13775916 | 0.80 | LMNA (0.51) | FDFT1ALDH1A1MAPTKDM4ENPC1 | |
| SCHEMBL13775927 | 0.79 | KDM4E (0.39) | FDFT1ALDH1A1MAPTKDM4ENPC1 | |
| SCHEMBL4117454 | 0.78 | FDFT1 (0.38) | FDFT1LPAR1ALDH1A1MAPT | |
| SCHEMBL13775919 | 0.77 | LMNA (0.40) | FDFT1ALDH1A1MAPTKDM4ENPC1 | |
| SCHEMBL13775845 | 0.77 | LPAR1 (0.41) | FDFT1LPAR1ALDH1A1MAPTKDM4E | |
| SCHEMBL4119083 | 0.77 | ALDH1A1 (0.39) | FDFT1LPAR1ALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1939205-A1 | TRICYCLIC COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | FDFT1, COASY, HMGCR | FDFT1 1/4885LPAR1 345/4885ATR 2779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.